



Atty. Dkt. No. 034536-1149

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Moosa MOHAMMADI et al.
Title: CRYSTALS OF THE TYROSINE KINASE DOMAIN OF NON-INSULIN
RECEPTOR TYROSINE KINASES
Appl. No.: 10/763,418
Filing Date: January 26, 2004
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop MISSING PARTS
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.*

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/664,526, filed 09/18/2000, now U.S. Patent No. 6,682,921, which is a continuation of application Serial No. 09/188,809, filed 11/09/1998, which is a continuation of application Serial No. 08/701,191, filed 08/21/1996, now U.S. Patent No. 5,942,428. As provided in 37 CFR §1.98(d), copies of the

documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.


Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.


Respectfully submitted,

Date 4 May 2004

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

By 

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/763,418
		Filing Date	01/26/2004
		First Named Inventor	Moosa MOHAMMADI
		Group Art Unit	Unassigned
Examiner Name	Unassigned	Attorney Docket Number	034536-1149
Sheet	1	of	13

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	5,217,999	A	LEVITZKI et al.	06-08-1993	
	A2	5,229,501	A	KEIFER et al.	07-20-1993	
	A3	5,302,606	A	SPADA et al.	04-12-1994	
	A4	5,330,992	A	EISSENSTAT et al.	07-19-1994	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A5	WO	91/15495	A1	PFIZER INC.	10-17-1991		
	A6	WO	92/13870	A	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	08-20-1992		
	A7	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL (HOLDINGS) INC.	11-26-1992		
	A8	WO	92/21660	A1	PFIZER INC.	12-10-1992		
	A9	WO	94/03427	A1	WARNER-LAMBERT COMPANY	02-17-1994		
	A10	WO	94/14808	A1	FARMITALIA CARLO ERBA S.R.L.	07-07-1994		
	A11	WO	96/40116	A1	SUGEN, INC.	12-19-1996		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/763,418
				Filing Date	01/26/2004
				First Named Inventor	Moosa MOHAMMADI
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	13	Attorney Docket Number	034536-1149

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A12	ADNANE et al., "BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers," <u>Oncogene</u> , 6:659-663 (1991), © Macmillan Press, Ltd.		
	A13	AKBASAK & SUNAR-AKBASAK et al., "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992), © Elsevier Science Publishers B.V.		
	A14	ARTEAGA et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <u>J. Clin. Invest.</u> 84:1418-1423, November 1989, © The American Society for Clinical Investigation, Inc.		
	A15	AUSUBEL et al. (editor), <u>Current Protocols in Molecular Biology</u> , John Wiley & Sons (1994) (TABLE OF CONTENTS FOR VOLS. 1 & 2)		
	A16	BARTLETT et al., "CAVEAT: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules," <u>Chemical and Biochemical Problems</u> 182-196 (1989)		
	A17	BASERGA, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-930, December 16, 1994, © Cell Press		
	A18	BASERGA, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252, January 15, 1995		
	A19	BASILICO & MOSCATELLI, "The FGF Family of Growth Factors and Oncogenes," <u>Adv. Cancer Res.</u> 59:115-165 (1992)		
	A20	BELLOT et al., "Ligand-induced transphosphorylation between different FGF receptors," <u>EMBO J.</u> 10:2849-2854 (1991)		
	A21	BELLUS et al., "A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia," <u>Nature Genetics</u> 10:357-359 (1995)		
	A22	BLAIKIE et al., "A Region in Shc Distinct from the SH2 Domain Can Bind Tyrosine-phosphorylated Growth Factor Receptors," <u>The Journal of Biological Chemistry</u> 269(51):32031-32034 (1994)		
	A23	BLUNDELL et al., "Knowledge-based protein modeling and design," <u>Eur. J. Biochem.</u> 172:513-520 (1988)		
	A24	BLUNDELL et al., <u>Protein Crystallography</u> , Academic Press (1976)(Table of Contents)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
		Application Number	10/763,418
(use as many sheets as necessary)		Filing Date	01/26/2004
		First Named Inventor	Moosa MOHAMMADI
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	3	of	13
		Attorney Docket Number	034536-1149

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A25	BOHM, "On the use of LUDI to search the Fine Chemicals Directory for ligands of proteins of known three-dimensional structure," <u>J. Comp. Aided Molec. Design</u> 8:623-632 (1994)	
	A26	BOLEN et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409, December 1992	
	A27	BOSSEMEYER et al., "Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from 2.0 Å structure of the complex with Mn ²⁺ adenylyl imidodiphosphate and inhibitor peptide PKI (5-24)," <u>EMBO J.</u> 12:849-859 (1993)	
	A28	BRANDEN et al., "Introduction to Protein Structure" <u>Garland Publishing Inc., New York</u> , pp. 269-273.	
	A29	BRUNGER, "Free R value: A novel statistical quantity for assessing the accuracy of crystal structures," <u>Nature</u> 355:472-475 (1992)	
	A30	BRUNGER, <u>X-Plor (version 3.1) Manual</u> (1992)(Table of Contents)	
	A31	BURGESS et al., "The fibroblast growth factor family: Multifunctional regulators of cell proliferation," <u>Cell Proliferation in Cancer</u> , Puszta et al., eds. Oxford University Press, Oxford; Ch. 7 pp. 154-195 (1994)	
	A32	BURGESS et al., "The heparin-binding (fibroblast) growth factor family of proteins," <u>Ann. Rev. Biochem.</u> 58:575-606 (1989)	
	A33	CANTLEY et al., "Oncogenes and Signal Transduction," <u>Cell</u> 64:281-302 (1991)	
	A34	CHAN et al., "Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is required for lymphocyte antigen receptor function," <u>EMBO J.</u> 14(11):2499-2508 (1995)	
	A35	CLARK et al., "Loss of three major auto phosphorylation sites in the EGF receptor does not block the mitogenic action of EGF," <u>Cell. Physiol.</u> 134(3):421-428 (1988)	
	A36	CLARK et al., "PRO LIGAND: An approach to de novo molecular design. 1. Application to the design of organic molecules," <u>J. Comp. Aided Molec. Design</u> 9:13-32 (1995)	
	A37	COLMAN, "Structure-based drug design," <u>Current Opinion in Struc. Biol.</u> 4:868-874 (1994)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
		Application Number	10/763,418
(use as many sheets as necessary)		Filing Date	01/26/2004
		First Named Inventor	Moosa MOHAMMADI
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	4	of	13
		Attorney Docket Number	034536-1149

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A38	COPPOLA et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14(7):4588-4595, July 1994, © American Society for Microbiology	
	A39	COWTAN, "dm": An automated procedure for phase improvement by density modification," <u>CCP4 and ESF-EACBM Newsletter</u> (joint) 31:34-38 (1994)	
	A40	COWTAN, "Protein Crystallography," <u>CCP4 and ESF-EACBM Newsletter</u> (joint) 31:34-38	
	A41	CREIGHTON, <u>Proteins: Structures and Molecular Principles</u> pp. 79-86, W.H. Freeman and Co., New York (1983)	
	A42	De BONDT, "Crystal Structure of Cyclin-Dependent Kinase 2," <u>Nature</u> 363:595-602, June 17, 1993	
	A43	DENG et al., "Fibroblast growth factor receptor 3 is a negative regulator of bone growth," <u>Cell</u> 84:911-92, March 22, 1996, © Cell Press	
	A44	DEVORE et al., "An FGF Receptor Signaling Pathway is Required for the Normal Cell Migrations of the Sex Myoblasts in C. elegans Hermaphrodites," <u>Cell</u> 83:611-620 (1995)	
	A45	DeVRIES et al., "The fms-like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991, February 21, 1992	
	A46	DICKSON et al., "Tyrosine kinase receptor – nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992), © Kluwer Academic Publishers, Boston, MA, USA	
	A47	DUCRUIX et al., <u>Crystallization of Nucleic Acids and Proteins: A Practical Approach</u> , IRL Press, Oxford, England (1992)(Table of Contents)	
	A48	ELLIS et al., "Replacement of insulin receptor tyrosine residues 1162 and 1163 comprises insulin-stimulated kinase activity and uptake of 2-deoxyglucose," <u>Cell</u> 45:721-732 (1986)	
	A49	FANTL et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules that Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423, May 1, 1992, © Cell Press	
	A50	FERRARA & HENZEL, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161(2):851-858, June 15, 1989, © Academic Press, Inc.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/763,418
				Filing Date	01/26/2004
				First Named Inventor	Moosa MOHAMMADI
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	5	of	13	Attorney Docket Number	034536-1149

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A51	FLOEGE et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," <u>Kidney International</u> 43:S47-S54, © International Society of Nephrology		
	A52	FLORES-RIVEROS et al., <u>J. Biol. Chem.</u> 264:21557-21572 (1989)		
	A53	FOLKMAN & KLAGSBRUN, "Angiogenic Factors," <u>Science</u> 235:442-447, January 23, 1987		
	A54	FOLKMAN & SHING, "Angiogenesis," <u>J. Biol. Chem.</u> 267(16):10931-10934, June 5, 1992, © The American Society for Biochemistry and Molecular Biology, Inc., USA		
	A55	FOLKMAN, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven, 583-296 (1987)		
	A56	FOLKMAN, "What is the Evidence that Tumors are Angiogenesis Dependent?" <u>Journal of the national Cancer Institute</u> , 82(1):4-6, January 3, 1990		
	A57	FRIESEL et al., "cDNA cloning and developmental expression of fibroblast growth factor receptors from <i>Xenopus laevis</i> ," <u>Mol. Cell. Biol.</u> 11(5):2481-2488 (1991)		
	A58	FRIESEL et al., "Spatially restricted expression of fibroblast growth factor receptor-2 during <i>Xenopus</i> development," <u>Development</u> 116(4):1051-1058 (1992)		
	A59	GIVOL et al., "Complexity of FGF receptors: Genetic basis for structural diversity and functional specificity," <u>FASEB J.</u> 6(15):3362-3369 (1992)		
	A60	GOLDSMITH et al., "Protein Kinases," <u>Current Opinion in Structural Biology</u> 4(6):833-840 (1994)		
	A61	GOODFORD, "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important macromolecules," <u>J. Med. Chem.</u> , 28:849-857 (1985)		
	A62	GOODSELL and OLSON, "Automated Docking of Substrates to Proteins by Simulated Annealing," <u>Proteins: Structure, Function, and Genetics</u> , 8:195-202 (1990)		
	A63	GOTOH et al., "A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor," <u>Biochem. Biophys. Res. Commun.</u> 186(2):768-774 (1992)		
	A64	GREER, "Model Structure for the Inflammatory Protein C5a," <u>Science</u> , 228:1055-1060 (1985)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/763,418
				Filing Date	01/26/2004
				First Named Inventor	Moosa MOHAMMADI
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	6	of	13	Attorney Docket Number	034536-1149

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A65	HENDRICKSON, "Transformations to optimize the superposition of similar structures," <u>Acta Crystallogr.</u> A35:158-163 (1979)		
	A66	HONEGGER et al., "Biological activities of EGF-receptor mutants with individually altered autophosphorylation sites," <u>EMBO J.</u> 7(10):3045-3052 (1988)		
	A67	HONEGGER et al., "Kinetic parameters of the protein tyrosine kinase activity of EGF-receptor mutants with individually altered autophosphorylation sites," <u>EMBO J.</u> 7:3053-3060 (1988)		
	A68	HOUCK et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>J. Biol. Chem.</u> , 267(36):26031-26037, December 25, 1992, © The American Society for Biochemistry and Molecular Biology, Inc., USA		
	A69	HU et al., "Insights into autoregulation from the crystal structure of twitchin kinase," <u>Nature</u> , 369:581-584 (1994)		
	A70	HUBBARD et al., "Crystal Structure of the Tyrosine Kinase Domain of the Human Insulin Receptor," <u>Nature</u> 372:746-754, December 1994		
	A71	HUNTER, "Protein kinase classification," <u>Methods Enzymol.</u> 200:3-37 (1991)		
	A72	JABS et al., "Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2," <u>Nature Genetics</u> , 8:275-279, November 1994		
	A73	JAYE et al., "Fibroblast growth factor receptor tyrosine kinases: Molecular analysis and signal transduction," <u>Biochimica et Biophysica Acta</u> , 1135:185-199 (1992), © Elsevier Science Publishers B.V.		
	A74	JEFFREY et al., "Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex," <u>Nature</u> 376:313-320 (1995)		
	A75	JOHNSON et al., "Active and inactive protein kinases: Structural basis for regulation" <u>Cell</u> 85:149-158 (1996)		
	A76	JOHNSON et al., "Structural and functional diversity in the FGF receptor multigene family," <u>Adv. Cancer Res.</u> 60:1-41 (1993)		
	A77	JONES et al., "Crystallization of authentic recombinant human growth hormone," <u>Biotechnology</u> , 5:499-500 (1987)		
	A78	JONES et al., "Interactive Computer Graphics: FREDO," <u>Methods in Enzymology</u> , 115:157-171 (1985)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/763,418
		Filing Date	01/26/2004
		First Named Inventor	Moosa MOHAMMADI
		Group Art Unit	Unassigned
Examiner Name	Unassigned		
Attorney Docket Number	034536-1149		
Sheet	7	of	13

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A79	KABSCH et al., "Dictionary of protein secondary structure: Pattern recognition of hydrogen bonded and geometrical features," <u>Biopolymers</u> 22:2577-2637 (1983)	
	A80	KLASBRUN and EDELMAN, "Biological and biochemical properties of fibroblast growth factors," <u>Arteriosclerosis</u> , 9:269-278, May/June 1989	
	A81	KLASBRUN and SOKER, "VEGF/VPF: the angiogenesis factor found?" <u>Current biology</u> , 3(10):699-7023 (1993)	
	A82	KLASBRUN et al., "A dual receptor system is required for basic fibroblast growth factor activity," <u>Cell</u> 67(2):229-231 (1991)	
	A83	KLAMBT et al., "Breathless, A Drosophila FGF receptor homolog, is essential for migration of tracheal and specific midline glial cells," <u>Genes & Development</u> 6:1668-1678 (1992)	
	A84	KLINE et al., "Studies by 1H Nuclear Magnetic Resonance and Distance Geometry of the Solution Conformation of the α -Amylase Inhibitor Tendamistat," <u>J. Molecular Biology</u> , 189:377-382 (1986)	
	A85	KMIECIK et al., "Activation and suppression of pp60 ^{c-src} transforming ability by mutation of its primary sites of tyrosine phosphorylation," <u>Cell</u> 49:65-73 (1987)	
	A86	KNIGHTON et al., "Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase," <u>Science</u> 253:407-414, July 26, 1991	
	A87	KNIGHTON et al., "Structural Basis of the Intrasteric Regulation of Myosin Light Chain Kinase," <u>Science</u> 258:130-135 (1992)	
	A88	KNIGHTON et al., 1991, "Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase," <u>Science</u> 253:407-414	
	A89	KOCH et al., "SH2 and SH3 Domains: Elements that control interactions of cytoplasmic signaling proteins," <u>Science</u> 252:668-674, May 3, 1991	
	A90	KOMADA et al., "Regulatory role of major tyrosine autophosphorylation site of kinase domain of c-Met receptor (scatter factor/hepatocyte growth factor receptor)," <u>J. Biol. Chem.</u> 269:16131-16136 (1994)	
	A91	KORC et al., "Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha," <u>J. Clin. Invest.</u> 90:1352-1360, October 1992, © The American Society for Clinical Investigation, Inc.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
		Application Number	10/763,418
(use as many sheets as necessary)		Filing Date	01/26/2004
		First Named Inventor	Moosa MOHAMMADI
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	8	of	13
		Attorney Docket Number	034536-1149

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A92	KUMABE et al., "Amplification of α -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633, (1992), © Macmillan Press Ltd.	
	A93	KUNTZ et al., "A geometric approach to macromolecule-ligand interactions," <u>J. Mol. Biol.</u> 162:269-288 (1982)	
	A94	KUNTZ et al., "Structure-based molecular design," <u>Acc. Chem. Res.</u> 27:117-123 (1994)	
	A95	KUSARI et al., "Insulin resistance an diabetes due to different mutations in the tyrosine kinase domain of both insulin receptor gene alleles," <u>J. Biol. Chem.</u> 266:5260-5267 (1991)	
	A96	LASKOWSKI et al., "Computer programs," <u>J. Appl. Cryst.</u> 26:283-291 (1993)	
	A97	LASKOWSKI et al., "PROCHECK: a computer program to check the stereochemical quality of protein structures," <u>J. Appl. Cryst.</u> 26:283-291 (1993)	
	A98	LATTMAN, "Use of the rotation and translation functions," <u>Methods in Enzymology</u> , 115:55-77 (1985)	
	A99	LEE and DONOGHUE, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," <u>Journal of Cell Biology</u> 118(5):1057-1070, September 1992, © The Rockefeller University Press	
	A100	LEVITZKI and GAZIT, "Tyrosine Kinase Inhibition: An Approach to Drug Development," <u>Science</u> 267:1782-1788 (1995)	
	A101	LONGATI et al., "Tyrosine ¹²³⁴⁻¹²³⁵ are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor) <u>Oncogene</u> 9:49-57 (1994)	
	A102	MACAULEY et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," <u>Cancer Research</u> 50:2511-2517, April 15, 1990	
	A103	MARCH et al., <u>Advanced Organic Chemistry: Reactions, Mechanism, and Structure</u> , New York, McGraw Hill (March 1994) (TABLE OF CONTENTS), John Wiley & Sons	
	A104	McPHERSON, "Current approaches to macromolecular crystallization," <u>Eur. J. Biochem.</u> 189:1-23 (1990), © FEBS	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/763,418
		Filing Date	01/26/2004
		First Named Inventor	Moosa MOHAMMADI
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	9	of	13
		Attorney Docket Number	034536-1149

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A105	MCPHERSON, <u>Preparation and Analysis of Protein Crystals</u> , John Wiley, New York (1982) (Table of Contents)	
	A106	MENG et al., "Automated docking with grid-based energy evaluation," <u>J. Comput. Chem.</u> 13:505-524 (1992)	
	A107	MIDDLEMAS et al., "Identification of TrkB autophosphorylation sites and evidence that phospholipase C- γ 1 is a substrate of the TrkB receptor," <u>J. Biol. Chem.</u> 269:5458-5466 (1994)	
	A108	MILLER et al., "FLOG: A system to select 'quasi-flexible' ligands complementary to a receptor of known three-dimensional structure," <u>J. Comp. Aided Molec. Design</u> 8:153-174 (1994)	
	A109	MIRANKER and KARPLUS, "Functionally maps of binding sites: A multiple copy of simultaneous search method," <u>Proteins: Structure, Function, and Genetics</u> 11:29-34 (1991)	
	A110	MOHAMMADI et al., "A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C- γ 1," <u>Mol. Cell. Biol.</u> 11:5068-5078 (1991)	
	A111	MOHAMMADI et al., "Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction," <u>Mol. Cell Biol.</u> 16:977-989, March 1996, © American Society for Microbiology	
	A112	MOHAMMADI et al., "Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism," <u>Cell</u> 86:577-587, August 23, 1996, © Cell Press	
	A113	MUENKE et al., "A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome," <u>Nature Genetics</u> 8:269-274, November 1994	
	A114	NASKI, "Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia," <u>Nature Genetics</u> 13:233-237 (1996)	
	A115	NAVAZA, "AMoRe: an automated package for molecular replacement," <u>Acta Cryst.</u> A50:157-163 (1994), © International Union of Crystallography, Great Britain	
	A116	NICHOLLS et al., "Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons," <u>Proteins</u> 11:281-296 (1991)	
	A117	ORNITZ et al., "Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells," <u>Mol. Cell. Biol.</u> 12(1):240-247 (1992)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/763,418
				Filing Date	01/26/2004
				First Named Inventor	Moosa MOHAMMADI
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-1149
Sheet	10	of	13		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A118	OTWINOWSKI, <u>Isomorphous Replacement and Anomalous Scattering</u> , Evans and Leslie eds. (Daresbury, United Kingdom: Daresbury Laboratory), 80-86 (1991)		
	A119	OTWINOWSKI, <u>Proceedings of the CCP4 Study Weekend</u> , Sawyer et al., eds. (Daresbury, United Kingdom: SERC Daresbury Laboratory), 56-62 (1993)		
	A120	PAWSON and SCHLESSINGER, "SH2 and SH3 domains," <u>Current Biology</u> 3(7):434-442 (1993)		
	A121	PETERS et al., "Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and ca ²⁺ flux but not mitogenesis," <u>Nature</u> 358:678-781 (1992)		
	A122	PFLUGRATH et al., "Crystal Structure Determination Refinement and the Molecular Model of the α -Amylase Inhibitor hoe-467 A," <u>J. Molecular Biology</u> 189:383-385 (1986)		
	A123	PIWNICA-WORMS et al., "Tyrosine phosphorylation regulates the biochemical and biological properties of pp60 ^{c-src} ," <u>Cell</u> 49:75-82 (1987)		
	A124	PLATE et al., "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas in vivo," <u>Nature</u> 359:845-848, October 29, 1994		
	A125	PLOWMAN et al., "Receptor Tyrosine kinases as Targets for Drug Intervention," <u>DN&P</u> 7(6):334-339, August 1994		
	A126	RODRIGUES et al., "Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase," <u>Oncogene</u> 9:2019-2027 (1994)		
	A127	ROSSMAN (ed.), "The molecular replacement method A collection of papers on the use of non-crystallographic symmetry," <u>Int. Sci. Rev. Ser.</u> No. 13, Gordon & Breach, New York (1972) (Table of Contents)		
	A128	SANDBERG-NORDQVIST et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," <u>Cancer Research</u> 53:2475-2478, June 1, 1993		
	A129	SCHLESSINGER and ULLRICH, "Growth Factor Signaling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391, September 1992, © Cell Press		
	A130	SCHLESSINGER et al., "Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors?" <u>Cell</u> 83:357-360, November 3, 1995, © Cell Press		

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/763,418
				Filing Date	01/26/2004
				First Named Inventor	Moosa MOHAMMADI
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	11	of	13	Attorney Docket Number	034536-1149

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A131	SHIANG et al., "Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia," <u>Cell</u> 78:335-342, July 29, 1994, © Cell Press		
	A132	SHIBUYA et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," <u>Oncogene</u> 5:519-524 (1990)		
	A133	SHISHIDO et al., "Two FGF-receptor homologues of Drosophila: one is expressed in mesodermal primordium in early embryos," <u>Development</u> 117:751-761 (1993)		
	A134	SHWEIKI et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," <u>Nature</u> 359:843-845, October 29, 1992		
	A135	SLAMON et al., "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer," <u>Science</u> 244:707-712, May 12, 1989		
	A136	SONGYANG et al., "SH2 domains recognize specific phosphopeptide sequences," <u>Cell</u> 72:767-778, March 23, 1993, © Cell Press		
	A137	SONGYANG et al., "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> , 14(4):2777-2785, April 1994, © American Society for Microbiology		
	A138	SPIVAK-KROIZMAN et al., "Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation," <u>Cell</u> 79:1015-1024 (1994)		
	A139	STEPHENS et al., "Trk receptors use redundant signal transduction pathways involving SHC and PLC-γ1 to mediate NGF response," <u>Neuron</u> 12:691-705 (1994)		
	A140	TAVORMINA et al., "Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3," <u>Nature Genetics</u> 9:321-328, March 1995		
	A141	TAYLOR et al., "How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase," <u>FASEB J.</u> 9(13):1255-1266 (1995)		
	A142	TAYLOR et al., "Three protein kinase structures define a common motif," <u>Structure</u> 2(5):345-355 (1994)		
	A143	TORP et al., "Expression of the epidermal growth factor receptor gene in human brain metastases," <u>AMPS</u> 100:713-719 (1992)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/763,418
				Filing Date	01/26/2004
				First Named Inventor	Moosa MOHAMMADI
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
(use as many sheets as necessary)				Attorney Docket Number	034536-1149
Sheet	12	of	13		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A144	TUZI et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)		
	A145	UENO et al., "A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor," <u>J. Biol. Chem.</u> 267:1470-1476 (1992)		
	A146	ULLRICH and SCHLESSINGER, "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> 61:203-212 (1990)		
	A147	VAISMAN et al., "Characterization of the receptors for vascular endothelial growth factor," <u>J. Biol. Chem.</u> 265:19461-19466, November 15, 1990, © The American Society for Biochemistry and Molecular Biology		
	A148	VAN DER GEER et al., 1994, "Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways," <u>Ann. Rev. Cell Biol.</u> 10:251-337		
	A149	VENKATARAMAN et al., "Preferential self-association of basic fibroblast growth factor is stabilized by heparin during receptor dimerization and activation," <u>Proc. Natl. Acad. Sci. USA</u> 93(2):845-850 (1996)		
	A150	WANGE et al., "Activating and inhibitory mutations in adjacent tyrosines in the kinase domain of ZAP-70," <u>J. Am. Chem. Soc.</u> 270(32):18730-18733 (1995)		
	A151	WEBER, "Physical Principles of Protein Crystallization," <u>Adv. Protein Chem.</u> 41:1-36 (1991)		
	A152	WEBSTER et al., "Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia," <u>EMBO J.</u> 15(3):520-527 (1996), © Oxford University Press		
	A153	WEI et al., "Expression, Characterization, and Crystallization of the Catalytic Fore of the Human Insulin Receptor Protein-tyrosine Kinase Domain," <u>Journal of Biological Chemistry</u> 270(14):8122-8130, April 7, 1995, © The American Society for Biochemistry and Molecular Biology, Inc., USA		
	A154	WEI et al., "Protein kinase superfamily – comparisons of sequence data with three-dimensional structures," <u>Current Opinion in Structural Biology</u> 4:450-455 (1994), © Current Biology Ltd.		
	A155	WEIDNER et al., "Tumor Angiogenesis and Metastasis – Correlation in Invasive Breast Carcinoma," <u>New England J. Medicine</u> 324(1):1-7, January 3, 1991, © the Massachusetts Medical Society, USA		
	A156	WUTHRICH, "Chapter 10, Three-Dimensional Protein Structures by NMR," <u>NMR of Protein and Nucleic Acids</u> 176-199 (1986)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/763,418
				Filing Date	01/26/2004
				First Named Inventor	Moosa MOHAMMADI
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	13	of	13	Attorney Docket Number	034536-1149

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.